NGMD — NuGen Medical Devices Income Statement
0.000.00%
- CA$7.95m
- CA$21.97m
- CA$1.01m
Annual income statement for NuGen Medical Devices, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0.138 | 0.152 | 0.331 | 1.01 |
| Cost of Revenue | ||||
| Gross Profit | 0.092 | 0.099 | 0.165 | 0.522 |
| Selling / General / Administrative Expenses | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 6.93 | 4.8 | 8.37 | 5.67 |
| Operating Profit | -6.79 | -4.64 | -8.04 | -4.66 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -7.1 | -5.57 | -9.33 | -5.22 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -7.11 | -5.58 | -9.36 | -5.23 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -7.11 | -5.58 | -9.36 | -5.23 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -7.11 | -5.58 | -9.36 | -5.23 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.112 | -0.063 | -0.056 | -0.026 |